Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 12,282 |
|
|||||
| News | - |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| enGene Holdings Inc | ENGNW | NASDAQ | Equity Warrant |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.06 | 4.14% | 1.51 | 15:00:25 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.16 | 1.06 | 1.77 | 1.51 | 1.45 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume |
|---|---|---|---|---|
| 110 | 12,282 | 1.50 | 18,468 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:00:00 | 127 | 1.51 | USD |
enGene Holdings Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 14.5k | 10.00k | - | 0 | -99.92M | -9,991.70 | 0.00 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News enGene
| Date | Time | Source | Heading |
|---|---|---|---|
| 11/13/2024 | 15:57 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of.. |
| 11/13/2024 | 15:53 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of.. |
| 10/28/2024 | 07:22 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 10/25/2024 | 07:10 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/22/2024 | 15:08 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 10/22/2024 | 15:07 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 10/22/2024 | 15:06 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of.. |
| 10/21/2024 | 08:21 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 10/21/2024 | 07:47 | Edgar (US Regulatory) | Form 8-K - Current report |
| 9/26/2024 | 06:40 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 9/26/2024 | 05:33 | Edgar (US Regulatory) | Form 8-K - Current report |
| 9/10/2024 | 15:53 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
ENGNW Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company's proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company's DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium. |
